Page last updated: 2024-12-07

12-deoxyphorbol 13-isobutyrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

12-deoxyphorbol 13-isobutyrate (PDB) is a potent tumor promoter. PDB is a synthetic analog of phorbol 12-myristate 13-acetate (PMA) which is a naturally occurring diterpene ester. PDB is an activator of protein kinase C (PKC) and has been shown to induce the expression of a variety of genes involved in cell proliferation, differentiation, and inflammation. PDB has been studied extensively as a tool for investigating the role of PKC in various biological processes. PDB is also being investigated as a potential therapeutic agent for the treatment of certain types of cancer. PDB is a powerful tool for investigating the role of PKC in various biological processes. PDB has been shown to activate PKC in a variety of cell types and has been used to study the effects of PKC activation on cell growth, differentiation, and apoptosis. PDB has also been used to study the role of PKC in inflammation, immune responses, and neurotransmission. PDB is a potential therapeutic agent for the treatment of certain types of cancer. PDB has been shown to inhibit the growth of various cancer cell lines in vitro and in vivo. PDB is also being investigated as a potential therapeutic agent for the treatment of other diseases such as Alzheimer's disease and Parkinson's disease. PDB is a potent tumor promoter. PDB has been shown to promote the growth of tumors in animal models. PDB is also a potent skin irritant. PDB has been shown to cause skin irritation and inflammation in humans. '

12-deoxyphorbol 13-isobutyrate: RN given refers to (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107855
CHEMBL ID528106
SCHEMBL ID16794671
MeSH IDM0117197

Synonyms (14)

Synonym
5h-cyclopropa[3,2-e]azulen-5-one, 1,1a.alpha.,1b.beta.,4,4a,7a.alpha.,7b,8,9,9a-decahydro-4a.beta.,7b.alpha.,9a.alpha.-trihydroxy-3-(hydroxymethyl)-1,1,6,8.alpha.-tetramethyl-, 9a-isobutyrate
propanoic acid, (1ar,1bs,4ar,7as,7br,8r,9as)-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa[3,4]benz[1,2-e]azulen-9a-yl ester
12-deoxyphorbol 13-isobutyrate
NSC632857 ,
25090-74-8
nsc-632857
12-deoxyphorbol-13-(2-methylpropionate)
propanoic acid, 2-methyl-, (1ar,1bs,4ar,7as,7br,8r,9as)-1,1a,1b4,4a,5,7a,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa(3,4)benz(1,2-e)azulen-9a-yl ester
5h-cyclopropa(3,4)benz(1,2-e)azulen-5-one, 1,1a-alpha,1b-beta,4,4a,7a-alpha,7b,8,9,9a-decahydro-4a-beta,7b-alpha,9a-alpha-trihydroxy-3-(hydroxymethyl)-1,1,6,8-alpha-tetramethyl-, 9a-isobutyrate
CHEMBL528106
SCHEMBL16794671
[(1r,2s,6r,10s,11r,13s,15r)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-13-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] 2-methylpropanoate
4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9ah-cyclopropa[3,4]benzo[1,2-e]azulen-9a-yl 2-methylpropanoate
DTXSID30947954
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID334632Skin irritant activity in NMRI mouse ear assessed as irritant dose 50 per ear after 24 hrs
AID334633Skin irritant activity in NMRI mouse ear assessed as irritancy 50 after 24 hrs
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (36.00)18.7374
1990's13 (52.00)18.2507
2000's3 (12.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.00 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]